Core Insights - Anixa Biosciences, Inc. is participating in the Water Tower Research Fireside Chat Series on December 15, 2025, with CEO Dr. Amit Kumar as a speaker [1][2] - The company focuses on cancer treatment and prevention, with a notable emphasis on ovarian cancer immunotherapy and vaccine development [2] Company Overview - Anixa is a clinical-stage biotechnology company specializing in cancer treatment and prevention [2] - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) [2] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers like lung, colon, and prostate [2] - The vaccines target "retired" proteins expressed in certain cancers, with exclusive licensing agreements in place with Cleveland Clinic for breast and ovarian cancer vaccines [2] Upcoming Events - The Fireside Chat will be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and is open to all investors [2] - Final data from Anixa's Phase 1 breast cancer vaccine trial will be presented on December 11, 2025, at the San Antonio Breast Cancer Symposium [5]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Powell Max Limited (PMAX) is up 38% at $3.15 [3] - Kaixin Holdings (KXIN) is up 34% at $4.16 [3] - SMX (Security Matters) Public Limited Company (SMX) is up 16% at $59.02 [3] - Anixa Biosciences, Inc. (ANIX) is up 14% at $4.80 [3] - American Eagle Outfitters, Inc. (AEO) is up 12% at $23.41 [3] - POET Technologies Inc. (POET) is up 11% at $5.21 [3] - Massimo Group (MAMO) is up 11% at $4.72 [3] - Marvell Technology, Inc. (MRVL) is up 10% at $102.60 [3] - Capricor Therapeutics, Inc. (CAPR) is up 8% at $6.92 [3] - Tharimmune, Inc. (THAR) is up 6% at $2.53 [3] Premarket Losers - Acadia Healthcare Company, Inc. (ACHC) is down 31% at $11.25 [4] - Aethlon Medical, Inc. (AEMD) is down 26% at $3.56 [4] - Polyrizon Ltd. (PLRZ) is down 19% at $5.92 [4] - CervoMed Inc. (CRVO) is down 16% at $6.85 [4] - TryHard Holdings Limited (THH) is down 15% at $19.01 [4] - Pure Storage, Inc. (PSTG) is down 14% at $80.93 [4] - AlphaTime Acquisition Corp (ATMC) is down 14% at $10.62 [4] - Leslie's, Inc. (LESL) is down 13% at $3.11 [4] - Lulu's Fashion Lounge Holdings, Inc. (LVLU) is down 11% at $4.56 [4] - Vistagen Therapeutics, Inc. (VTGN) is down 5% at $3.39 [4]

Core Insights - Anixa Biosciences is a clinical stage biotech company focused on developing innovative CAR-T cell therapy for ovarian cancer and a vaccine for breast cancer [2] Company Overview - Anixa is listed on NASDAQ under the ticker ANIX [2] - The company is engaged in the development of additional predevelopment candidates beyond its primary therapies [2] Leadership - Dr. Amit Kumar serves as the Chairman and CEO of Anixa Biosciences [1]

Core Insights - Anixa Biosciences has received approval from the WHO for the non-proprietary name "liraltagene autoleucel" for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant milestone in its development and potential commercialization [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) therapy, which targets the follicle stimulating hormone receptor (FSHR) expressed on ovarian cells and certain cancer cells [3][4] Clinical Development - The ongoing Phase 1 trial of liraltagene autoleucel is designed to evaluate safety, identify the maximum tolerated dose, and monitor clinical activity in adult women with recurrent ovarian cancer who have progressed after at least two prior therapies [3][4] - The trial is being conducted in partnership with Moffitt Cancer Center, a leader in cancer immunotherapy [2][4] Future Directions - The approval of the non-proprietary name allows Anixa to establish a universally recognized name for its CAR-T therapy, facilitating clearer identification and safe prescription of the drug [2][3] - The company plans to transition to using the name liraltagene autoleucel, or lira-cel, in future communications [2]

Group 1 - Water Tower Research (WTR) experienced a technical issue during a recent Fireside Chat with Anixa Biosciences, leading to an interruption in the live broadcast [1] - The session was fully recorded and is now available for on-demand viewing [1] - WTR's CEO, Shawn Severson, apologized for the inconvenience and stated that the technical issue has been resolved to ensure future sessions proceed without interruption [1] Group 2 - The Fireside Chat Series by Water Tower Research aims to connect investors with management teams from innovative public and private companies through open-access discussions [1] - Water Tower Research focuses on modernizing investor engagement through research-driven communications, providing equal access to high-quality company research for all investors [3] - The company distributes its research and investor content across various platforms, including traditional research aggregators and social media, to enhance investor relations [3]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology, which targets the -lactalbumin protein, a promising approach for immunoprevention strategies against breast cancer [1][2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a strong emphasis on developing next-generation preventive immunotherapies [2][5] - The company has a collaboration with Cleveland Clinic for the development of its breast cancer vaccine, which is part of a broader portfolio that includes ovarian cancer immunotherapy [5] Patent and Intellectual Property - The U.S. Patent Number 12,472,205 will be issued on November 18, 2025, extending the intellectual property protection for Anixa's breast cancer vaccine technology into the mid-2040s [1][2] - This patent reinforces the company's commitment to addressing breast cancer, which is projected to affect nearly 300,000 women in the U.S. by 2026 [1][3] Market Need - Breast cancer remains the most commonly diagnosed cancer among women globally, with over 297,000 new cases expected in the U.S. in 2025 and approximately 43,000 deaths anticipated [3] - There is currently no FDA-approved vaccine for breast cancer prevention, highlighting a significant unmet need in preventive oncology [3] Vaccine Mechanism - Anixa's investigational vaccine aims to stimulate the immune system to recognize and eliminate cells expressing -lactalbumin while sparing normal tissue, potentially minimizing off-target effects [4]

Core Insights - Anixa Biosciences, Inc. is a biotechnology company focused on cancer treatment and prevention, with its Chairman and CEO, Dr. Amit Kumar, participating in the Water Tower Research Fireside Chat Series on November 11, 2025 [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) [2]. - The company is also developing vaccines in collaboration with Cleveland Clinic to treat and prevent breast and ovarian cancers, as well as other vaccines targeting high incidence malignancies such as lung, colon, and prostate cancers [2]. - Anixa's business model involves partnerships with renowned research institutions throughout all stages of development, allowing for the exploration of emerging technologies for further development and commercialization [2]. Clinical Programs - The breast cancer vaccine is currently in Phase 1 clinical trial status [5].

Core Insights - Anixa Biosciences has executed a data transfer agreement with Cleveland Clinic, marking a significant step in transferring the breast cancer vaccine clinical trial data and sponsorship to Anixa for future clinical development [1][2][4] Group 1: Clinical Development - Enrollment for the Phase 1 trial has been completed, showing encouraging immune response data, leading Anixa to advance the vaccine into a Phase 2 clinical trial [2] - The IND, currently sponsored by Cleveland Clinic, is in the process of being transferred to Anixa, allowing the company to assume full sponsorship [2][4] Group 2: Vaccine Technology - The breast cancer vaccine targets -lactalbumin, a protein typically expressed in breast tissue during lactation, which re-emerges in various forms of breast cancer [3] - By establishing an immune response against -lactalbumin-expressing cells, the vaccine may provide both therapeutic and preventive benefits for patients with tumors expressing this protein [3] Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company’s vaccine portfolio includes vaccines for breast and ovarian cancer, as well as additional vaccines targeting other cancers, developed in collaboration with Cleveland Clinic [4]

Core Insights - Anixa Biosciences has received a patent for its breast cancer vaccine technology in China, extending intellectual property protection until 2040, which enhances its global patent portfolio and supports future commercialization strategies [1][3]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [5]. Vaccine Technology - The breast cancer vaccine targets human-lactalbumin, a protein linked to lactation that is abnormally expressed in certain breast cancers, aiming to prime the immune system to prevent tumor formation without damaging normal tissue [2][4]. Clinical Development - A Phase 1 clinical trial for the breast cancer vaccine has been completed, with full results to be presented at the San Antonio Breast Cancer Symposium on December 11, 2025 [4]. Intellectual Property Strategy - The newly issued patent reinforces Anixa's intellectual property strategy, allowing for broader international development and commercialization opportunities in regions with high breast cancer incidence [3][4].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: ANIXA BIOSCIENCES INC - ANIXA BIOSCIENCES INC currently holds a Momentum Style Score of B, indicating a positive outlook based on price changes and earnings estimate revisions [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Price Performance - Over the past week, ANIX shares have increased by 32.42%, while the Zacks Medical - Biomedical and Genetics industry has decreased by 0.34% [5] - In a longer timeframe, ANIX shares have risen by 30.56% over the past month, compared to the industry's 6.3% performance [5] - Over the last three months, ANIX shares have gained 30.56%, and over the past year, they have increased by 47.16%, significantly outperforming the S&P 500, which moved 6.17% and 14.81% respectively [6] Trading Volume - ANIX's average 20-day trading volume is 281,328 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, one earnings estimate for ANIX has increased, while none have decreased, leading to a consensus estimate rise from -$0.38 to -$0.35 [9] - For the next fiscal year, one estimate has moved upwards with no downward revisions, indicating a positive trend in earnings expectations [9] Conclusion - Given the strong price performance, positive earnings outlook, and favorable momentum indicators, ANIXA BIOSCIENCES INC is positioned as a promising investment opportunity [11]